George Matcham
Vermogen: 275 844 $ op 30-09-2026
Vermogen: 275 844 $ op 30-09-2026
George Matcham is currently an Independent Director at Instil Bio, Inc. since 2018.
Formerly, Dr. Matcham was a Non-Executive Director at Chimeric Therapeutics Ltd. (Australia) from 2021 to 2023.
From 2017 to 2018, Dr. Matcham was SVP-CAR T CMC & Technology Development at Celgene Corp.
Dr. Matcham also served as Chief Operating Officer at Celgene Cellular Therapeutics.
Education includes graduate studies at the University of Cambridge and undergraduate and doctorate degrees from the University of Cardiff.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
INSTIL BIO, INC. 0,56% | 11-06-2026 | 38.100 ( 0,56% ) | 275 844 $ | 30-09-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| INSTIL BIO, INC. | Directeur/Bestuurslid | 01-09-2018 |
| Bedrijven | Functie | Einde |
|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Directeur/Bestuurslid | 03-08-2023 |
| CELGENE | Corporate Officer/Principal | 01-06-2018 |
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Develops human pharmaceuticals | Operationeel Directeur | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 6 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cardiff
University of Cardiff Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Develops human pharmaceuticals | Health Technology |
Instil Bio, Inc.
Instil Bio, Inc. BiotechnologyHealth Technology Develops tumour infiltrating lymphocytes for the treatment of cancer | Health Technology |
Chimeric Therapeutics Ltd. (Australia)
Chimeric Therapeutics Ltd. (Australia) BiotechnologyHealth Technology Develops cell therapies for the tumors | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau